TWO STUDIES DEMONSTRATE SIGNIFICANT BENEFIT OF ELOXATIN– BASED CHEMOTHERAPY COMBINED WITH BEVACIZUMAB IN ADVANCED COLORECTAL CANCER

TWO STUDIES DEMONSTRATE SIGNIFICANT BENEFIT OF ELOXATIN– BASED CHEMOTHERAPY COMBINED WITH BEVACIZUMAB IN ADVANCED COLORECTAL CANCER Positive Results of TREE-2 and ECOG 3200 Trials Presented at the 2005 Gastrointestinal Cancers Symposium in Hollywood, Florida PARIS, France, January 31, 2005 – Sanofi-aventis (NYSE: SNY) announced today preliminary results of two large prospective trials evaluating the safety and efficacy of Eloxatin® (oxaliplatin for injection) -based regimens in the treatment of metastatic colorectal cancer. These data were presented at the Gastrointestinal Cancers Symposium, co-sponsored by the American Society of Clinical Oncology (ASCO), the American Gastroenterological Association (AGA), the American Society for Therapeutic Radiology and Oncology (ASTRO), and the Society of Surgical Oncology (SSO). For complete press release, se attached file! ------------------------------------------------------------ Ytterligere informasjon kan hentes på følgende hjemmeside: http://www.waymaker.no Nedenstående filer kan lastes ned: http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=67999&fn=wkr0010.pdf Press release, pdf